Titre : Transmission synaptique

Transmission synaptique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Inactivating Agents
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Transmission synaptique : Questions médicales les plus fréquentes", "headline": "Transmission synaptique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Transmission synaptique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-29", "dateModified": "2025-02-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Transmission synaptique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phénomènes physiologiques du système nerveux", "url": "https://questionsmedicales.fr/mesh/D009424", "about": { "@type": "MedicalCondition", "name": "Phénomènes physiologiques du système nerveux", "code": { "@type": "MedicalCode", "code": "D009424", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Potentiels synaptiques", "alternateName": "Synaptic Potentials", "url": "https://questionsmedicales.fr/mesh/D055366", "about": { "@type": "MedicalCondition", "name": "Potentiels synaptiques", "code": { "@type": "MedicalCode", "code": "D055366", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561.830.750" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Potentiels post-synaptiques excitateurs", "alternateName": "Excitatory Postsynaptic Potentials", "url": "https://questionsmedicales.fr/mesh/D019706", "about": { "@type": "MedicalCondition", "name": "Potentiels post-synaptiques excitateurs", "code": { "@type": "MedicalCode", "code": "D019706", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561.830.750.199" } } }, { "@type": "MedicalWebPage", "name": "Potentiels post-synaptiques inhibiteurs", "alternateName": "Inhibitory Postsynaptic Potentials", "url": "https://questionsmedicales.fr/mesh/D053444", "about": { "@type": "MedicalCondition", "name": "Potentiels post-synaptiques inhibiteurs", "code": { "@type": "MedicalCode", "code": "D053444", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561.830.750.400" } } }, { "@type": "MedicalWebPage", "name": "Potentiels post-synaptiques miniatures", "alternateName": "Miniature Postsynaptic Potentials", "url": "https://questionsmedicales.fr/mesh/D055369", "about": { "@type": "MedicalCondition", "name": "Potentiels post-synaptiques miniatures", "code": { "@type": "MedicalCode", "code": "D055369", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561.830.750.560" } } }, { "@type": "MedicalWebPage", "name": "Sommation des potentiels post-synaptiques", "alternateName": "Postsynaptic Potential Summation", "url": "https://questionsmedicales.fr/mesh/D059227", "about": { "@type": "MedicalCondition", "name": "Sommation des potentiels post-synaptiques", "code": { "@type": "MedicalCode", "code": "D059227", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G11.561.830.750.780" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Transmission synaptique", "alternateName": "Synaptic Transmission", "code": { "@type": "MedicalCode", "code": "D009435", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Dietmar Schmitz", "url": "https://questionsmedicales.fr/author/Dietmar%20Schmitz", "affiliation": { "@type": "Organization", "name": "Neuroscience Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. dietmar.schmitz@charite.de." } }, { "@type": "Person", "name": "Christian Lüscher", "url": "https://questionsmedicales.fr/author/Christian%20L%C3%BCscher", "affiliation": { "@type": "Organization", "name": "Department of Basic Neurosciences, Medical Faculty, University of Geneva, CH-1211 Geneva, Switzerland. christian.luscher@unige.ch." } }, { "@type": "Person", "name": "James E Rothman", "url": "https://questionsmedicales.fr/author/James%20E%20Rothman", "affiliation": { "@type": "Organization", "name": "Nanobiology Institute and Department of Cell Biology, Yale University, New Haven, CT, USA." } }, { "@type": "Person", "name": "Kirill Grushin", "url": "https://questionsmedicales.fr/author/Kirill%20Grushin", "affiliation": { "@type": "Organization", "name": "Nanobiology Institute and Department of Cell Biology, Yale University, New Haven, CT, USA." } }, { "@type": "Person", "name": "Manindra Bera", "url": "https://questionsmedicales.fr/author/Manindra%20Bera", "affiliation": { "@type": "Organization", "name": "Nanobiology Institute and Department of Cell Biology, Yale University, New Haven, CT, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37149117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clim.2023.109629" } }, { "@type": "ScholarlyArticle", "name": "Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36732204", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.blre.2023.101041" } }, { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35945604", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02126-2" } }, { "@type": "ScholarlyArticle", "name": "Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.", "datePublished": "2022-10-06", "url": "https://questionsmedicales.fr/article/36201560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pntd.0010809" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques de l'appareil locomoteur et du système nerveux", "item": "https://questionsmedicales.fr/mesh/D055687" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes physiologiques du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009424" }, { "@type": "ListItem", "position": 4, "name": "Transmission synaptique", "item": "https://questionsmedicales.fr/mesh/D009435" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Transmission synaptique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Transmission synaptique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Transmission synaptique", "description": "Comment diagnostiquer un dysfonctionnement synaptique ?\nQuels examens sont utilisés pour évaluer la transmission synaptique ?\nQuels symptômes indiquent un problème de transmission synaptique ?\nPeut-on mesurer la transmission synaptique directement ?\nQuels marqueurs biologiques sont associés à la transmission synaptique ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Transmission synaptique", "description": "Quels symptômes sont liés à une transmission synaptique altérée ?\nComment la dépression affecte-t-elle la transmission synaptique ?\nLes troubles de l'humeur sont-ils liés à la transmission synaptique ?\nQuels signes neurologiques peuvent indiquer un problème synaptique ?\nLa fatigue chronique est-elle liée à la transmission synaptique ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Transmission synaptique", "description": "Comment prévenir les troubles de la transmission synaptique ?\nLe stress affecte-t-il la transmission synaptique ?\nL'exercice physique influence-t-il la transmission synaptique ?\nLes habitudes de sommeil affectent-elles la transmission synaptique ?\nLa méditation peut-elle améliorer la transmission synaptique ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Transmission synaptique", "description": "Quels traitements existent pour améliorer la transmission synaptique ?\nLa thérapie cognitive peut-elle aider la transmission synaptique ?\nLes suppléments alimentaires influencent-ils la transmission synaptique ?\nComment la stimulation cérébrale affecte-t-elle la transmission synaptique ?\nLes thérapies comportementales aident-elles la transmission synaptique ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Transmission synaptique", "description": "Quelles complications peuvent résulter d'une transmission synaptique altérée ?\nLes maladies neurodégénératives affectent-elles la transmission synaptique ?\nComment les troubles de l'apprentissage sont-ils liés à la transmission synaptique ?\nLes troubles psychotiques sont-ils liés à la transmission synaptique ?\nLa schizophrénie affecte-t-elle la transmission synaptique ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Transmission synaptique", "description": "Quels facteurs de risque influencent la transmission synaptique ?\nL'alimentation joue-t-elle un rôle dans la transmission synaptique ?\nLe tabagisme affecte-t-il la transmission synaptique ?\nLes maladies chroniques influencent-elles la transmission synaptique ?\nLe manque d'activité physique est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D009435?mesh_terms=Complement+Inactivating+Agents&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un dysfonctionnement synaptique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests électrophysiologiques et des imageries cérébrales peuvent être utilisés." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer la transmission synaptique ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM fonctionnelle et l'électroencéphalogramme (EEG) sont couramment utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème de transmission synaptique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la mémoire, des convulsions ou des changements de comportement peuvent survenir." } }, { "@type": "Question", "name": "Peut-on mesurer la transmission synaptique directement ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la microscopie à fluorescence permettent d'observer la transmission." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés à la transmission synaptique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des protéines comme la synaptophysine peuvent servir de marqueurs pour la synapse." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une transmission synaptique altérée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes incluent des troubles cognitifs, des spasmes musculaires et des douleurs." } }, { "@type": "Question", "name": "Comment la dépression affecte-t-elle la transmission synaptique ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "La dépression peut réduire la plasticité synaptique, affectant la communication neuronale." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils liés à la transmission synaptique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres dans les neurotransmetteurs peuvent provoquer des troubles de l'humeur." } }, { "@type": "Question", "name": "Quels signes neurologiques peuvent indiquer un problème synaptique ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent des tremblements, des troubles de la coordination et des réflexes anormaux." } }, { "@type": "Question", "name": "La fatigue chronique est-elle liée à la transmission synaptique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans la transmission synaptique peuvent contribuer à la fatigue chronique." } }, { "@type": "Question", "name": "Comment prévenir les troubles de la transmission synaptique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est essentiel." } }, { "@type": "Question", "name": "Le stress affecte-t-il la transmission synaptique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut altérer la transmission synaptique et la plasticité." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la transmission synaptique ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier favorise la santé neuronale et la transmission synaptique." } }, { "@type": "Question", "name": "Les habitudes de sommeil affectent-elles la transmission synaptique ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un sommeil de qualité est crucial pour la régénération synaptique et cognitive." } }, { "@type": "Question", "name": "La méditation peut-elle améliorer la transmission synaptique ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la méditation peut augmenter la plasticité synaptique et réduire le stress." } }, { "@type": "Question", "name": "Quels traitements existent pour améliorer la transmission synaptique ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les antidépresseurs et les nootropiques peuvent être utilisés." } }, { "@type": "Question", "name": "La thérapie cognitive peut-elle aider la transmission synaptique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut améliorer la plasticité synaptique et la fonction cognitive." } }, { "@type": "Question", "name": "Les suppléments alimentaires influencent-ils la transmission synaptique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments comme les oméga-3 peuvent favoriser la santé synaptique." } }, { "@type": "Question", "name": "Comment la stimulation cérébrale affecte-t-elle la transmission synaptique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La stimulation cérébrale peut renforcer les connexions synaptiques et améliorer la fonction." } }, { "@type": "Question", "name": "Les thérapies comportementales aident-elles la transmission synaptique ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent améliorer les interactions neuronales et la plasticité synaptique." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une transmission synaptique altérée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles neurologiques, des troubles de l'humeur et des crises." } }, { "@type": "Question", "name": "Les maladies neurodégénératives affectent-elles la transmission synaptique ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme Alzheimer altèrent gravement la transmission synaptique." } }, { "@type": "Question", "name": "Comment les troubles de l'apprentissage sont-ils liés à la transmission synaptique ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la transmission synaptique peuvent entraîner des difficultés d'apprentissage." } }, { "@type": "Question", "name": "Les troubles psychotiques sont-ils liés à la transmission synaptique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres dans les neurotransmetteurs peuvent contribuer aux troubles psychotiques." } }, { "@type": "Question", "name": "La schizophrénie affecte-t-elle la transmission synaptique ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la schizophrénie est associée à des dysfonctionnements dans la transmission synaptique." } }, { "@type": "Question", "name": "Quels facteurs de risque influencent la transmission synaptique ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le stress et la génétique peuvent influencer la transmission." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la transmission synaptique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en nutriments favorise une transmission synaptique saine." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la transmission synaptique ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut altérer la fonction synaptique et augmenter le risque de troubles." } }, { "@type": "Question", "name": "Les maladies chroniques influencent-elles la transmission synaptique ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète peuvent affecter la transmission synaptique." } }, { "@type": "Question", "name": "Le manque d'activité physique est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inactivité physique peut nuire à la santé synaptique et cognitive." } } ] } ] }

Sources (10000 au total)

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement act...

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.

The efficacy and safety of complement inhibition in COVID-19 patients is unclear.... A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO... 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea... Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...

Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.

Enteroaggregative Escherichia coli (EAEC) is a predominant but neglected enteric pathogen implicated in infantile diarrhoea and nutrient malabsorption. There are no non-antibiotic approaches to dealin... We used EAEC strains, 042 and MND005E in a medium-throughput crystal violet-based antibiofilm screen. Hits were confirmed in concentration-dependence, growth kinetic and time course assays and activit... In all, five compounds (1.25%) reproducibly inhibited biofilm accumulation by at least one strain by 30-85% while inhibiting growth by under 10%. Hits exhibited potent antibiofilm activity at concentr... This study identified five compounds, not previously described as anti-adhesins or Gram-negative antibacterials, with significant EAEC antibiofilm activity. Molecule, MMV687800 targets the EAEC Aap. I...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.

We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future num...

Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.

A male in his teens with a history of liver transplant for biliary atresia (aged 2 years) and autoimmune haemolytic anaemia (AIHA, aged 6 years) presented with jaundice, dark urine, fatigue and chest ...

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. This post hoc analys... Patients with PNH and hemoglobin ≥10.0 g/dL at baseline of PADDOCK (N = 6), PRINCE (N = 8), and PEGASUS (N = 11) were included. Before receiving pegcetacoplan, PADDOCK and PRINCE patients were C5i-nai... From baseline to week 16, mean (SD) hemoglobin concentrations increased in C5i-naive patients (PADDOCK: 10.5 [0.4] to 12.7 [1.1] g/dL; PRINCE: 11.3 [1.0] to 14.0 [1.3] g/dL) and those with suboptimal ... Patients with PNH and mild/moderate anemia who were C5i-naive or who had suboptimal hemoglobin concentrations despite eculizumab treatment had improved hematologic outcomes and reduced fatigue after i... Trial registration numbers: PADDOCK (NCT02588833), PRINCE (NCT04085601; EudraCT, 2018-004220-11), PEGASUS (NCT03500549)....